Physician profile
Veronica Dunfee
NPI 1265997373
$831.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $34.48 · 2024: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.25 | 2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $182.64 | 2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $169.21 | 2023-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $46.67 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.36 | 2024 | |
| Amneal Pharmaceuticals LLC | $37.33 | 2024 | Unithroid |
| Astellas Pharma US INC | $37.06 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $26.76 | 2024 | Spravato |
| Exact Sciences Corporation | $23.48 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $21.91 | 2024 | |
| Abbvie INC. | $21.22 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.83 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $16.00 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Dunfee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.